Apr 012024
Date |
Brand Name(s) |
Description |
Type |
Reason |
Company |
| 4/1/2024 | AVpak | Atovaquone Oral Suspension, USP 750mg/5mL | Drugs | Potential Bacillus cereus contamination | AvKARE, LLC |
Date |
Brand Name(s) |
Description |
Type |
Reason |
Company |
| 4/1/2024 | AVpak | Atovaquone Oral Suspension, USP 750mg/5mL | Drugs | Potential Bacillus cereus contamination | AvKARE, LLC |
Sorry, the comment form is closed at this time.